
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics is a biopharmaceutical company with a promising pipeline of therapies, including Obe-cel and Aucatzyl, that target various diseases such as B-ALL, autoimmune diseases, progressive MS, and lupus nephritis. The company has shown positive results in trials for pediatric patients and is investing in improvements to address manufacturing challenges. While there are risks associated with investing in a development-stage company, Autolus has the potential to provide new and improved treatments for a range of diseases and has a potential revenue stream from Aucatzyl with an estimated annual price of $525,000.
Bears say
Autolus Therapeutics is facing major risks in the commercialization of their CAR-T therapies, with potential concerns regarding safety and long-term efficacy as most patients eventually experience relapse. In addition, the company is heavily reliant on their lead asset, Aucatzyl, for future revenue as their pipeline-in-a-product strategy for B-cell depleting disorders may not yield the desired results. Furthermore, Autolus is facing stiff competition in the CAR-T market and may struggle to capture market share, resulting in potentially low sales and financial performance in the near term.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares